A Phase II Trial of Dovitinib in Bacillus Calmette-Guerin(BCG) Refractory Urothelial Carcinoma Patients With Tumor Fibroblast Growth Factor Receptor 3(FGFR3) Mutations or Over-expression: Hoosier Cancer Research Network GU12-157
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Aug 2017
At a glance
- Drugs Dovitinib (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 21 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2017.
- 10 Jun 2017 Biomarkers information updated
- 06 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jul 2017.